ClinicalTrials.gg
CompletedNCT00726752Updated May 23, 2012Results posted

A Study In Patients With Advanced Solid Tumor

A Phase 1 interventional study of Axitinib (AG-013736) in Neoplasms, sponsored by Pfizer. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-05-23.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • solid tumor
  • Axitinib
  • Pharmacokinetics
  • Phase 1
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 6 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients or cytologically diagnosed with advanced solid tumors
  • Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies
  • (ECOG) Performance Status (PS) of 0, 1 or 2
  • Patients with no uncontrolled hypertension

Exclusion criteria

Exclusion Criteria:

  • Patients who have central lung lesions involving major blood vessels
  • Patients who require anticoagulant therapy.
  • Patients with active epilepsy seizure or symptoms, with requiring treatment, with spinal cord compression and with carcinomatous meningitis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Axitinib

    Drug: Axitinib (AG-013736)

Interventions

  • Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.

06

What researchers measure

Primary outcomes

  1. Single Dose: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf)

    AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose

  3. Single Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose

  4. Single Dose: Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose

Secondary outcomes

  1. Multiple Dose: Maximum Observed Plasma Concentration (Cmax)

    Cmax at multiple dosing

    Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose

  2. Multiple Dose: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    The dosing interval was 12 hours in this study.

    Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose

  3. Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax at multiple dosing

    Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose

  4. Multiple Dose: Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau)

    Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)

    Time frame: Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose

  5. Percent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 1, 2, and 3 (s-VEGFR1, s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT )

    Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., s-VEGFR1, VEGFR2, s-VEGFR3, s-KIT, and VEGF

    Time frame: Prior to the initial dose (baseline) and Day 1 of Cycle 2

  6. Number of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

    CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

    Time frame: Up to 470 days

  7. Number of Participants With Adverse Events

    Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grade 3 or higher , serious adverse events, and adverse events resulted in discontinuation.

    Time frame: Up to 470 days of treatment plus 28-days follow-up

07

Results

Posted Mar 26, 2012

Participant flow

Participant flow — Overall Study
MilestoneAG-013736
Started6
Completed0
Not completed6
Withdrew: Lack of efficacy6

Outcome measures

PrimarySingle Dose: Maximum Observed Plasma Concentration (Cmax)
Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Reported as:
Mean · ng/mL
Single Dose: Maximum Observed Plasma Concentration (Cmax)
ng/mLAG-013736
5 mg Single Dose20.732 ± 14.492
7 mg Single Dose32.007 ± 28.223
10 mg Single Dose53.123 ± 60.921
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf)

AUCinf is obtained from AUC (0 - t) plus AUC (t - infinity).

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Time Infinity (AUCinf)
ng*hr/mLAG-013736
5 mg Single Dose180.25 ± 154.90
7 mg Single Dose228.45 ± 183.12
10 mg Single Dose379.12 ± 345.50
PrimarySingle Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Reported as:
Median · hours
Single Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursAG-013736
5 mg Single Dose4.1000 (3.950 to 6.020)
7 mg Single Dose4.0000 (0.983 to 9.880)
10 mg Single Dose4.0150 (2.050 to 6.000)
PrimarySingle Dose: Plasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 10, 24, and 32-hour postdose
Reported as:
Mean · hours
Single Dose: Plasma Decay Half-Life (t1/2)
hoursAG-013736
5 mg Single Dose4.778 ± 2.815
7 mg Single Dose5.088 ± 2.592
10 mg Single Dose5.880 ± 3.456
SecondaryMultiple Dose: Maximum Observed Plasma Concentration (Cmax)

Cmax at multiple dosing

Time frame:
Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Reported as:
Mean · ng/mL
Multiple Dose: Maximum Observed Plasma Concentration (Cmax)
ng/mLAG-013736
Multiple Dose: Maximum Observed Plasma Concentration (Cmax)25.933 ± 21.703
SecondaryMultiple Dose: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

The dosing interval was 12 hours in this study.

Time frame:
Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Reported as:
Mean · ng*h/mL
Multiple Dose: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
ng*h/mLAG-013736
Multiple Dose: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)164.55 ± 128.15
SecondaryMultiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)

Tmax at multiple dosing

Time frame:
Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Reported as:
Median · hours
Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)
hoursAG-013736
Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)4.0400 (3.930 to 7.700)
SecondaryMultiple Dose: Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau)

Rac Cmax is obtained from Cmax (Cycle 1, Day 15) divided by Cmax (Cycle 1, Day 1) Rac AUCtau is obtained from AUCtau (Cycle 1, Day 15) divided by AUCtau (Cycle 1, Day 1)

Time frame:
Cycle 1 Day 15 predose in the morning, and 0.5, 1, 2, 4, 8 and 12 hour postdose
Reported as:
Mean · ratio
Multiple Dose: Accumulation Ratio for Cmax (Rac Cmax) and Accumulation Ratio for AUCtau (Rac AUCtau)
ratioAG-013736
Rac Cmax1.3540 ± 0.5335
Rac AUCtau1.4185 ± 0.3951
SecondaryPercent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 1, 2, and 3 (s-VEGFR1, s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT )

Percent change from baseline is obtained from (observed value minus baseline value) divided by baseline value multiplied by 100 in each parameter, i.e., s-VEGFR1, VEGFR2, s-VEGFR3, s-KIT, and VEGF

Time frame:
Prior to the initial dose (baseline) and Day 1 of Cycle 2
Reported as:
Median · percent
Percent Change From Baseline in Soluble Vascular Endothelial Growth Factor Receptor 1, 2, and 3 (s-VEGFR1, s-VEGFR2 and s-VEGFR3), Vascular Endothelial Growth Factor (VEGF), Soluble Stem Cell Factor Receptor (s-KIT )
percentAG-013736
s-VEGFR1-29.15 (-31.4 to -25.3)
s-VEGFR2-33.16 (-58.4 to -26.2)
s-VEGFR3-56.38 (-66.2 to -42.1)
s-KIT-14.59 (-23.7 to -5.2)
VEGF179.52 (37.0 to 1444.6)
SecondaryNumber of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)

CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters (SLD) of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as PD being demonstrated during the first 8 weeks. PD was defined as at least a 20% increase in the SLD of target lesions compared to the smallest SLD since the study treatment started.

Time frame:
Up to 470 days
Reported as:
Number · participants
Number of Participants With Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression of Disease (PD) According to the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
participantsAG-013736
CR0
PR0
SD3
PD3
SecondaryNumber of Participants With Adverse Events

Number of participants with any adverse events, adverse events graded as Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grade 3 or higher , serious adverse events, and adverse events resulted in discontinuation.

Time frame:
Up to 470 days of treatment plus 28-days follow-up
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsAG-013736
Any adverse events6
Any serious adverse events1
Any Grade-3 or -4 adverse events4
Any Grade-5 adverse events (= death)1
Discontinuation due to adverse events0

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG-013736—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventAG-013736
Disease progressionGeneral disorders1/6
Most frequent other events
Showing 10 of 61
Most frequent other events
EventAG-013736
FatigueGeneral disorders5/6
HypertensionVascular disorders5/6
Blood thyroid stimulating hormone increasedInvestigations4/6
ProteinuriaRenal and urinary disorders4/6
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders4/6
DiarrhoeaGastrointestinal disorders3/6
Blood alkaline phosphatase increasedInvestigations3/6
Blood amylase increasedInvestigations3/6
Blood lactate dehydrogenase increasedInvestigations3/6
Decreased appetiteMetabolism and nutrition disorders3/6

Baseline characteristics

Age Continuous
Age Continuous(years)AG-013736
Mean53.8 ± 15.8
Sex: Female, Male
Sex: Female, Male(Participants)AG-013736
Female3
Male3
08

Study locations

1 site
  • Pfizer Investigational Site
    Kobe-shi, Hyogo-ken, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2008
First posted
Aug 1, 2008
Start
Jul 2008
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Mar 26, 2012
Last update
May 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00726752
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 1, 2008
Start date
Jul 2008
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Mar 26, 2012
Last update
May 23, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion